Dr. Verma Discusses Clinical Trial Endpoints in Metastatic Breast Cancer

Dr. Verma on Palbociclib Plus Fulvestrant for HR+/HER2- Breast CancerПодробнее

Dr. Verma talks about clinical trials at SunnybrookПодробнее

Dr. Verma on Targeting HER2 in Early-Stage Breast CancerПодробнее

Dr. Verma on Targeting HER2 in Patients With Early-Stage DiseaseПодробнее

Dr. Verma on the Future of the Treatment of HER2-Positive Breast CancerПодробнее

Dr. Kimberly Blackwell Discusses the T-DM1 EMILIA Trial Coprimary EndpointsПодробнее

Dr. Verma on Immunotherapy in HER2+ Breast CancerПодробнее

Dr. Verma on Advances in the Treatment of Metastatic HER2-Positive Breast CancerПодробнее

Dr. Verma on Advancements in Treatment of HER2-Positive Breast CancerПодробнее

Dr. Hurvitz on Therapeutics for HER2+ Metastatic Breast CancerПодробнее

Exploring clinical trials for breast cancer - Mayo ClinicПодробнее

Dr. Matthew Galsky on PFS as an Endpoint in Urothelial Cancer TrialsПодробнее

Drs. Kuerer, Gradishar & McArthur discuss #breastcancer from #ASBrS22 - https://bit.ly/3JOwU1gПодробнее

Dr. Verma on Clinical TrialsПодробнее

Dr. Rugo on Results of Oral Paclitaxel With Encequidar in Metastatic Breast CancerПодробнее

Dr. Baselga Discusses the CLEOPATRA Pertuzumab TrialПодробнее

Dr. Verma on Evolving Standards of HER2-Positive Breast CancerПодробнее

Buparlisib helps overcome endocrine resistance in metastatic breast cancer: BELLE-2 trial resultsПодробнее

Dr. Rugo Discusses Guidelines for Metastatic Breast Cancer ManagementПодробнее